KRMD
KORU Medical Systems, Inc.
KRMD's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over KRMD overall, supported by stronger modeled upside and stronger fundamentals.
KRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
KRMD's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
KRMD PE Valuation
KRMD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 226x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
KRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect KRMD to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
KRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | — |
| Q3 2026 | -$0.02 | +$0.07 |
| Q2 2026 | -$0.04 | +$0.06 |
| Q1 2026 | -$0.05 | +$0.07 |
| Q4 2025 | -$0.06 | +$0.07 |
| Q3 2025 | -$0.09 | +$0.17 |
| Q2 2025 | -$0.10 | +$0.16 |
| Q1 2025 | -$0.12 | +$0.17 |
| Q4 2024 | -$0.13 | +$0.17 |
KRMD is still losing money, but far less than before: $0.02 per share over the past year, against $0.30 at its worst in late 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over KRMD on earnings quality, reporting a profit while its opponent remains loss making.
KRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +11% |
| Q2 2026 | $12M | +18% |
| Q1 2026 | $11.8M | +22% |
| Q4 2025 | $10.9M | +23% |
| Q3 2025 | $10.4M | +27% |
| Q2 2025 | $10.2M | +21% |
| Q1 2025 | $9.6M | +18% |
| Q4 2024 | $8.8M | +23% |
KRMD's revenue has grown year over year for 11 quarters in a row: $12M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.6% | +10 points |
| Q2 2026 | 5.2% | +8.3 points |
| Q1 2026 | -7.3% | +5.6 points |
| Q4 2025 | -5% | +13 points |
| Q3 2025 | -8.3% | +13 points |
| Q2 2025 | -3.1% | +11 points |
| Q1 2025 | -13% | +11 points |
| Q4 2024 | -18% | +13 points |
KRMD's operating margin was 1.6% last quarter, up 10 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over KRMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over KRMD on profitability, with a higher operating margin.
KRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2M | -8973% |
| Q2 2026 | $108.2K | +$597.4K |
| Q1 2026 | -$31.5K | +$649.4K |
| Q4 2025 | $687K | -30% |
| Q3 2025 | $13K | +$2M |
| Q2 2025 | -$489.2K | -$376.2K |
| Q1 2025 | -$680.9K | -$201.1K |
| Q4 2024 | $983.2K | +9.2% |
KRMD has burned cash in most quarters: −$387,369 over the past year, against −$173,904 the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over KRMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
KRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.6% | -2.8M shares |
| 1 year | +1.1% | +493K shares |
| 3 years | +2.4% | +1.1M shares |
| 5 years | +5.4% | +2.4M shares |
| Available history | +20% | +7.7M shares |
KRMD has 47M diluted shares, up 1.1% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over KRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
KRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -37.0x | Net Cash |
| Q3 2020 | -239.5x | Net Cash |
| Q2 2020 | -60.9x | Net Cash |
| Q1 2020 | -3.6x | Net Cash |
| Q4 2019 | -6.3x | Net Cash |
KRMD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
KRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 30.9 | Neutral |
KRMD's weekly RSI is 53 (neutral) and its Stochastic is 31 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
KRMD PE vs Healthcare Sector
| Metric | KRMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KRMD has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
KRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.13 | 18% above |
| 20 week MA | $3.45 | 7% above |
| 50 week MA | $4.20 | 12% below |
| 100 week MA | $3.92 | 5.9% below |
| 200 week MA | $3.39 | 8.8% above |
KRMD's trend is mixed: it's above three of its five weekly moving averages, and 8.8% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over KRMD on trend strength, trading above more of its moving averages.
KRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.15 | $6.09 | -1% |
| 2021 | $6.09 | $3.25 | -47% |
| 2022 | $3.25 | $3.42 | +5.2% |
| 2023 | $3.42 | $2.46 | -28% |
| 2024 | $2.46 | $3.94 | +60% |
| 2025 | $3.94 | $6.23 | +58% |
| 2026 YTD | $6.23 | $3.69 | -41% |
KRMD has finished lower in three of the last six years. It's down 41% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over KRMD on returns for 2026, with the stronger performance.